Dr Alan Burguete-Torres (Mexico) reviews recent data on immunotherapy in gastroesophageal cancer.


Introduction

Hello, I’m Dr Alan Burguete and I would like to welcome you to this GI CONNECT video newsletter.

I am really happy to share with you today some of the major advances that we saw in 2020 regarding the role of immunotherapy in upper GI cancer.

CheckMate-649

The first message I would like to share with you, is that we now have a new standard of care in the first-line, advanced setting for gastric cancer. The CheckMate-649 trial demonstrated a 3-month overall survival benefit in patients with PD-L1 CPS score ≥5 with a combination of nivolumab plus standard, platinum-based, chemotherapy. One of the caveats of this trial is that this was a PD-L1 enriched population, with over 60% of patients having a CPS score ≥5 and might not reflect what we see in the general population.

KEYNOTE-590

The second, practice changing trial for patients with advanced oesophageal cancer is the KEYNOTE-590 study which also demonstrated a benefit in progression-free and overall survival, particularly in patients with squamous oesophageal and PD-L1 expression with a CPS score ≥10.

CheckMate-577

The last trial I would like to share with you is CheckMate-577, which also demonstrated a substantial benefit in progression-free survival with the addition of nivolumab in the adjuvant setting for patients with oesophageal cancer who were treated with neoadjuvant chemoradiotherapy and surgery.

Conclusion

So these are, in my opinion, the three most important advances regarding the role of immunotherapy in upper GI cancers.

I hope this information was useful for you and I hope to see you soon. Thanks for watching.

Dr Alan Burguete-Torres M.D. is a dedicated gastrointestinal oncologist and Associate Professor of Medicine at the University of Nuevo Leon in Monterrey, Mexico. He earned his medical degree and completed a 4-year Internal Medicine fellowship at Tecnológico de Monterrey and later completed a 3-year fellowship in Medical Oncology at the University of Nuevo Leon. He later attended University of Valencia – INCLIVA Biomedical Research Institute for a short-term fellowship in gastrointestinal oncology under the mentorship of Prof. Andrés Cervantes in Valencia, Spain. He is currently Head of the Gastrointestinal Tumors Unit at the University of Nuevo León Cancer Center and actively participates and coordinates GI oncology MDT meetings at both private and public institutions. Currently, Dr Burguete-Torres has his private practice in gastrointestinal oncology at ONCARE Cancer Center and Centro Médico Zambrano Hellion – Tecnológico de Monterrey. He is also member of the European Society of Digestive Oncology (ESDO), European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO) and Mexican Society of Oncology (SMEO). His main research interest is in colorectal and gastroesophageal cancers.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer and BeiGene Europe.

Meet the experts

Other programmes of interest

video Video
Oncology 
ER+ metastatic breast cancer: Elacestrant and beyond

Follow a patient's journey during and post-elacestrant treatment for ER+/HER2- metastatic breast cancer

Experts
Prof. Maria Vittoria Dieci
Endorsed by
GRASP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2024

Educational programme supported by an independent medical education grant from Menarini Stemline Oncology.
podcast Podcast

Episode

3

of 3

episode
Oncology 
Ovarian Cancer: Pre-analytical phase challenges and biomarker testing

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar Feb 2024

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.
micro-learning Micro learning

Module

2

of 2

module
Oncology 
PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 2 - Evolving landscape of PARPi in mCRPC: Combination with anti-androgens

Experts
Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno
Endorsed by
ZERO EAUN
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca
micro-learning Micro learning

Module

1

of 2

module
Oncology 
PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 1 - PARP inhibitors in advanced prostate cancer

Experts
Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno
Endorsed by
ZERO EAUN
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca
interactive-patient-case Interactive patient case

Episode

2

of 2

episode
Oncology 
Advanced HCC: Treatment options for patients ineligible for IO

Explore treatment options, adverse event management and next steps in this interactive patient case

Experts
Prof. Sammy Saab
Endorsed by
Blue Faery Digestive Cancers Europe 5th anniversary
Global Liver Institute
  • clock 15 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from Bayer.
podcast Podcast

Episode

2

of 3

episode
Oncology 
Lung Cancer: Pre-analytical phase challenges and biomarker testing

Moderated by the Oncology Brothers. Episode 2 of a 3-part video podcast series

Experts
Dr Bruna Pellini, Dr Semir Vranić, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.